SCHEMBL13429299

SCHEMBL13429299

CN(C)CCNc1ccc(-c2cccc(Oc3cc(=O)[nH]c4ccccc34)c2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
GAA P10253 1/20 0.43
TLR9 Q9NR96 2/20 0.41
TLR8 Q9NR97 1/20 0.41
TLR7 Q9NYK1 1/20 0.41
PRKCB P05771 1/20 0.37
PRKCA P17252 1/20 0.37
PRKCH P24723 1/20 0.37
PRKCE Q02156 1/20 0.37
PRKCQ Q04759 1/20 0.37
PRKCD Q05655 1/20 0.37
PIM1 P11309 2/20 0.36
PIM3 Q86V86 2/20 0.36
PIM2 Q9P1W9 2/20 0.36
TERT O14746 1/20 0.36
KDM4E B2RXH2 2/20 0.36
F2 P00734 1/20 0.36
HSD17B10 Q99714 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3216980 0.87 ATM (0.49) MEN1KMT2A
SCHEMBL3202232 0.87 MEN1 (0.43) MEN1KMT2AGAAKDM4EHPGD
SCHEMBL13429221 0.85 JAK2 (0.48) TLR9TLR8TLR7KDM4EF2
SCHEMBL3224822 0.82 DRD2 (0.42) MEN1KMT2AGAATLR9TLR8
SCHEMBL13429223 0.82 FYN (0.49) TLR9TLR8TLR7KDM4EHSD17B10
SCHEMBL13429296 0.82 LTA4H (0.41) MEN1KMT2AGAATLR9TLR8
SCHEMBL13429161 0.81 HPGD (0.54) MEN1KMT2AKDM4EHSD17B10HPGD
SCHEMBL13429278 0.80 PIP4K2A (0.43) MEN1KMT2AGAAPRKCDHPGD
SCHEMBL3214163 0.80 KDM4E (0.48) MEN1KMT2AKDM4EHPGDSMN1; SMN2
SCHEMBL13429248 0.80 EPHX1 (0.45) MEN1KMT2AGAAF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS MTOR, RICTOR, PIK3CA MEN1 2648/4885KMT2A 2445/4885GAA 1227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.